Bioequivalence Study of Amoxicillin Dispersible 600 mg Tablets Under Fasting Conditions
Ranbaxy Laboratories Limited
This study compared the relative bioavailability (rate and extent of absorption) of
amoxicillin tablets for oral suspension 600 mg by Ranbaxy Laboratories Limited with that of
Amoxil ® for oral suspension 400 mg/ 5 mL by SmithKline Beecham Pharmaceuticals following
single oral dose (600 mg) in healthy, adult, subjects under fasting conditions using a
randomized two-way crossover design.
This study is prospective, open-label, randomized, crossover, single dose, with 02
treatments, 02 sequences and 02 periods. The volunteers received, in each period, the
reference or the test formulation, according to the randomization list, under fasting
conditions, in order to evaluate if the reference and test formulations are bioequivalent.
An Open-Label Trial Of Reduced- Dose Pylera, Amoxicillin, and Esomeprazole in the Treatment Of Helicobacter Pylori Infection
American University of Beirut Medical Center
Over the years, it has become clear that the first-line triple therapy is losing efficacy
worldwide. A capsule containing 3 agents (Pylera®) containing 125mg metronidazole, 140mg
bismuth subcitrate potassium, and 125mg tetracycline was made available.
The efficacy of the Pylera capsule was studied in a randomized control trial, in which a
quadruple Pylera therapy (Pylera capsule and a PPI) was evaluated against the standard
triple regimen. In the study, 3 three-in-one capsules were taken four times daily (after
meals and at bedtime).
Given the above, we aim at assessing the effectiveness of fewer pills per day of the Pylera
capsule (3 Pylera capsules supplemented with the addition of amoxicillin and esomeprazole
twice daily; sum of 10 pills/day for 10 days) in the eradication of H. pylori.
Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia.
Not yet recruiting
St. Justine's Hospital
Phase 2/Phase 3
The aim of this study will be to evaluate whether a twice-daily antibiotic regimen is
non-inferior to a thrice-daily regimen for the treatment of non-severe community acquired
pneumonia in children presenting at a paediatric Emergency Department (ED).
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.